跳至主要内容
临床试验/NCT00092482
NCT00092482已完成3 期

Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)

Merck Sharp & Dohme LLC0 个研究点目标入组 3,882 人开始时间: 2002年6月28日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
3,882
主要终点
Tolerability and immune responses at week 4 post dose 3.

研究概览

简要总结

The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
16 Years 至 23 Years(Child, Adult)
性别
Female
接受健康志愿者

入选标准

  • Female with an intact uterus with lifetime history of 0-4 sexual partners

排除标准

  • Prior Human Papillomavirus Vaccine (HPV) vaccination;
  • Prior abnormal paps;
  • Prior history of genital warts

结局指标

主要结局

Tolerability and immune responses at week 4 post dose 3.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验